TL;DR
PD-1 blockade, a cornerstone of cancer immunotherapy, can paradoxically boost immunosuppressive T regulatory cells (Tregs), hindering treatment efficacy. This study reveals that activated CD8 T cells, not Tregs themselves, drive this Treg accumulation through IL-2 production, which upregulates ICOS on Tregs. Blocking this CD8-Treg crosstalk via ICOS inhibition before PD-1 therapy significantly improves anti-tumor responses, offering a novel strategy to enhance immunotherapy.
What Problem Does This Paper Address?
Cancer immunotherapy, particularly using PD-1 blockade, has revolutionized cancer treatment by unleashing the immune system's ability to fight tumors. However, a significant challenge is that many patients either don't respond or eventually relapse. One proposed reason for this resistance is the presence of tumor-infiltrating T regulatory cells (Tregs), which actively suppress anti-tumor immune responses. While inhibiting Tregs is a promising strategy, the precise mechanisms by which PD-1 blockade influences these immunosuppressive cells remain unclear. This paper aims to unravel how PD-1 blockade affects tumor Tregs and to identify a way to overcome this immunosuppressive effect to improve immunotherapy outcomes.
Methods
The researchers employed a multi-pronged approach:
- Mouse Models: They used both immunogenic (D4M-S) and non-immunogenic (D4M) melanoma models in mice, along with MC38 colon carcinoma models.
- Immunotherapy: They administered anti-PD-1 (αPD-1) antibodies, a standard immunotherapy.
- Cell Depletion and Blocking: They used CD8-depleting antibodies and IL-2 neutralizing antibodies to investigate the roles of these components.
- Intravital Microscopy (F-IVM): This advanced technique allowed real-time visualization of Treg behavior and calcium signaling within living tumors.
- Genetic Manipulation: They used genetically modified mice to selectively delete PD-1 on Tregs or to track IL-2 production.
- Flow Cytometry: This was used extensively to quantify cell populations, measure protein expression (e.g., Ki67, ICOS, GITR), and analyze cytokine production.
- Meta-Analysis: They analyzed publicly available human patient data to see if their findings translated to humans.
- CellChat Analysis: This computational tool was used to infer cell-cell communication pathways in human melanoma data.
Datasets
The study utilized:
- Mouse Tumor Models: D4M, D4M-S (melanoma), and MC38 (colon carcinoma) cell lines.
- Human Melanoma Datasets: Publicly available single-cell RNA sequencing data from Sade-Feldman et al. (2018) and bulk RNA sequencing data from Riaz et al. (2017), Gide et al. (2019), and Helmink et al. (2020).
Key Insights and Ideas
- CD8 Cells are the Unexpected Drivers: The most surprising finding is that activated CD8 T cells, not Tregs themselves, are the primary drivers of Treg accumulation during PD-1 blockade. This challenges the assumption that PD-1 blockade directly impacts Tregs.
- The IL-2/ICOS Axis is Crucial: CD8 T cells, upon activation by PD-1 blockade, produce IL-2. This IL-2 then acts on Tregs, upregulating the anti-apoptotic protein ICOS, which leads to their increased survival and accumulation.
- Tumor Immunogenicity Matters: The effect of PD-1 blockade on Treg accumulation was significantly more pronounced in immunogenic tumors (like D4M-S) compared to non-immunogenic ones.
- Interrupting the Crosstalk is Key: Blocking the interaction between CD8 cells and Tregs, specifically by inhibiting ICOS signaling, before initiating PD-1 therapy, dramatically improved tumor control in mice. This suggests a strategic window for intervention.
- Human Relevance: The findings in mice were supported by meta-analysis of human melanoma patient data and computational analysis of human tumor transcriptomes, indicating that this CD8-Treg-IL-2-ICOS axis is relevant in human cancer.
Key Results
- PD-1 blockade significantly increased the numbers of tumor Tregs in immunogenic melanoma models and in human melanoma patients.
- This Treg increase was not due to cell-intrinsic PD-1 signaling in Tregs but rather an indirect effect mediated by CD8 T cells.
- CD8 T cells, colocalized with Tregs in tumors, produced IL-2 after PD-1 blockade.
- IL-2 upregulated ICOS on tumor Tregs, promoting their accumulation.
- Inhibiting ICOS signaling before PD-1 immunotherapy led to increased control of immunogenic melanoma.
- Meta-analysis of human melanoma patients showed a significant increase in tumor Tregs after PD-1 monotherapy.
- CellChat analysis predicted an upregulated CD8/IL-2/Treg communication axis in human melanomas treated with PD-1 blockade.
Limitations and Future Work
- Complexity of Treg Accumulation: While the CD8-IL-2-ICOS axis is a major contributor, the authors acknowledge that it might not be the sole mechanism responsible for Treg accumulation after PD-1 immunotherapy. Other factors could also play a role.
- ICOSL Blockade Synergy: Concomitant blockade of ICOSL and PD-1 did not improve immunotherapy effectiveness, suggesting that ICOSL blockade also impacts effector T cells. However, sequential administration (ICOSL blockade first, then PD-1) showed significant synergy, highlighting the importance of timing.
- Future Directions: The authors suggest that targeting the CD8-mediated, IL-2-dependent support to Tregs within the tumor microenvironment could be a promising strategy to enhance immunotherapy efficacy without causing widespread Treg depletion and autoimmunity. Further investigation into the precise timing and combination strategies for ICOSL and PD-1 blockade is warranted.
Summary updated